Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling

Ch Li, Rr Bies, Y. Wang, Mr Sharma, S. Karovic, L. Werk, Mj Edelman, Aa Miller, Ee Vokes, A. Oto, Mj Ratain, Lh Schwartz, Ml Maitland

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Quantitative assessments of tumor burden and modeling of longitudinal growth could improve phase II oncology trials. To identify obstacles to wider use of quantitative measures we obtained recorded linear tumor measurements from three published lung cancer trials. Model-based parameters of tumor burden change were estimated and compared with similarly sized samples from separate trials. Time-to-tumor growth (TTG) was computed from measurements recorded on case report forms and a second radiologist blinded to the form data. Response Evaluation Criteria in Solid Tumors (RECIST)-based progression-free survival (PFS) measures were perfectly concordant between the original forms data and the blinded radiologist re-evaluation (intraclass correlation coefficient = 1), but these routine interrater differences in the identification and measurement of target lesions were associated with an average 18-week delay (range, -20 to 55 weeks) in TTG (intraclass correlation coefficient = 0.32). To exploit computational metrics for improving statistical power in small clinical trials will require increased precision of tumor burden assessments.

Original languageEnglish
Pages (from-to)43-50
Number of pages8
JournalClinical and Translational Science
Issue number1
StatePublished - Jan 2016


  • Antineoplastic agents/pharmacology
  • Clinical trials
  • Humans
  • Lung neoplasms/drug therapy
  • Models
  • Response Evaluation Criteria in Solid Tumors
  • Statistical
  • Tomography
  • X-ray computed


Dive into the research topics of 'Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling'. Together they form a unique fingerprint.

Cite this